JPS6354321A - 血糖降下剤 - Google Patents

血糖降下剤

Info

Publication number
JPS6354321A
JPS6354321A JP61061833A JP6183386A JPS6354321A JP S6354321 A JPS6354321 A JP S6354321A JP 61061833 A JP61061833 A JP 61061833A JP 6183386 A JP6183386 A JP 6183386A JP S6354321 A JPS6354321 A JP S6354321A
Authority
JP
Japan
Prior art keywords
group
carbon atoms
substituent
formula
phenylalanine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP61061833A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0415221B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html
Inventor
Shigeru Toyoshima
豊島　滋
Yoshiko Seto
瀬戸　淑子
Hisashi Shinkai
久 新海
Kouji Toi
戸井　浤二
Izumi Kumashiro
熊代　泉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of JPS6354321A publication Critical patent/JPS6354321A/ja
Publication of JPH0415221B2 publication Critical patent/JPH0415221B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP61061833A 1985-03-27 1986-03-19 血糖降下剤 Granted JPS6354321A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP60-62276 1985-03-27
JP6227685 1985-03-27
JP61-38111 1986-02-22

Publications (2)

Publication Number Publication Date
JPS6354321A true JPS6354321A (ja) 1988-03-08
JPH0415221B2 JPH0415221B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-03-17

Family

ID=13195452

Family Applications (1)

Application Number Title Priority Date Filing Date
JP61061833A Granted JPS6354321A (ja) 1985-03-27 1986-03-19 血糖降下剤

Country Status (4)

Country Link
US (2) US4816484A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0196222B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS6354321A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE10199054I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0395717U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1990-01-23 1991-09-30
WO1998022105A1 (fr) * 1996-11-15 1998-05-28 Ajinomoto Co., Inc. Preparation en comprimes
WO2001068136A1 (fr) * 2000-03-17 2001-09-20 Ajinomoto Co., Inc. Medicaments permettant de traiter les complications du diabete et des neuropathies et utilisation de ces medicaments
WO2002034713A1 (fr) * 2000-10-24 2002-05-02 Ajinomoto Co.,Inc. Procede de production de cristaux de nateglinide a forme b
JP2005519949A (ja) * 2002-03-11 2005-07-07 ノバルティス アクチエンゲゼルシャフト ナテグリニドの塩
JP2005522503A (ja) * 2002-04-15 2005-07-28 ノバルティス アクチエンゲゼルシャフト Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形
JP2007505059A (ja) * 2003-09-11 2007-03-08 ゾルファイ フルーオル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｎ−アシル化合物の製造
JP2007526890A (ja) * 2003-07-10 2007-09-20 リヒター ゲデオン ベジェセティ ジャール アール．テー． キラル純ｎ−（トランス−４−イソプロピル−シクロヘキシルカルボニル）−ｄ−フェニルアラニン及びそれらの結晶構造変性体の生成方法
WO2007119580A1 (ja) * 2006-03-31 2007-10-25 Ajinomoto Co., Inc. カルボン酸クロリド化合物の製造方法
US7659428B2 (en) 2000-10-18 2010-02-09 Ajinomoto Co., Inc. Methods for producing acylphenylalanine
WO2017090656A1 (ja) * 2015-11-27 2017-06-01 住友化学株式会社 トランス－シクロヘキサンカルボン酸の製造方法

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676056B1 (fr) * 1991-05-03 1993-07-16 Adir Nouveaux derives du benzopyranne leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
DE69217762T2 (de) * 1991-07-30 1997-10-09 Ajinomoto Kk Kristalle von N-(Trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
US5466864A (en) * 1993-02-25 1995-11-14 Ajinomoto Co., Inc. Method for recovering L-phenylalanine
US5831118A (en) * 1996-06-18 1998-11-03 Katayama Seiyakusyo Co., Ltd. Epimerization of 2- or 4- substituted cyclohexanecarboxylic acids
US20040176457A1 (en) * 2003-02-27 2004-09-09 Hemmingsen Lisbeth Tofte Novel NIDDM regimen
DK0991619T3 (da) 1997-06-23 2003-12-29 Tanabe Seiyaku Co Inhibitorer af alfa 4-beta 1-medieret celleadhæsion
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
CO5200844A1 (es) * 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
AU2005200818B2 (en) * 1999-09-17 2008-07-17 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
ITMI20002019A1 (it) * 1999-09-17 2002-03-15 Novartis Ag Metodo per il trattemento dei disturbi metabolici, in particolare diabete oppure una malattia oppure una condizione associate con il diabete
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US20030139434A1 (en) 2000-01-21 2003-07-24 Bork Balkan Combinations comprising dipeptidylpeptidase-iv inhibitor
AR033390A1 (es) 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
MXPA03003484A (es) * 2000-10-18 2003-07-14 Ajinomoto Kk Procedimiento para producir cristales de nateglinida.
MXPA03003686A (es) * 2000-10-24 2004-01-26 Ajinomoto Kk Preparaciones hidrofilas de farmaco que contienen nateglinida.
US6740776B2 (en) * 2001-07-16 2004-05-25 Novartis Ag Air oxidation of an aromatic aldehyde to an aromatic acid
CN1335182A (zh) * 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
US20050101638A1 (en) * 2002-11-08 2005-05-12 Webb Randy L. Combination of organic compounds
US7411089B2 (en) 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals
AU2003236243A1 (en) * 2002-04-15 2003-10-27 Ajinomoto Co., Inc. Novel nateglinide crystal
CN100363332C (zh) * 2002-04-26 2008-01-23 中国人民解放军军事医学科学院毒物药物研究所 芳香性氨基酸衍生物，其制备方法及其医药用途
HUP0500259A2 (hu) 2002-04-29 2005-06-28 Biocon Limited Új N-(transz-4-izopropil-ciklohexil-karbonil)-D-fenil-alanin forma, eljárás előállítására és alkalmazása
RU2324676C2 (ru) * 2002-04-29 2008-05-20 Байокон Лимитид Кристаллический n-(транс-4-изопропилциклогексилкарбонил)-d-фенилаланин формы с для лечения сахарного диабета типа 2 и способ его получения
KR100983990B1 (ko) * 2002-05-28 2010-09-30 아지노모토 가부시키가이샤 Ａｔｐ 시트르산 리아제의 발현 억제용 의약 조성물
US20050096367A1 (en) * 2002-05-28 2005-05-05 Yoshiro Kitahara Pharmaceutical composition for suppression of the expression of ATP citrate lyase and use thereof
US6861553B2 (en) * 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
CN100384813C (zh) * 2002-07-03 2008-04-30 特瓦制药工业有限公司 制备那格列奈及其中间体的方法
US20050075400A1 (en) * 2002-07-18 2005-04-07 Ronit Yahalomi Polymorphic forms of nateglinide
US7420084B2 (en) * 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7148376B2 (en) * 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) * 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7358390B2 (en) * 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
EP1467964A1 (en) * 2002-07-18 2004-10-20 Teva Pharmaceutical Industries Limited Polymorphic forms of nateglinide
JP2006513250A (ja) * 2003-01-28 2006-04-20 中国科学院上海薬物研究所 アラニン系化合物、その製造方法及び用途
JPWO2004074330A1 (ja) * 2003-02-18 2006-06-01 コニシ株式会社 硬化性樹脂、その製造方法及び硬化性樹脂組成物
US8173840B2 (en) * 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
US7589233B2 (en) * 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
PT1675625E (pt) 2003-09-17 2013-05-23 Univ Texas Imagiologia de células beta pancreáticas direccionada com base no mecanismo
CA2563793A1 (en) * 2004-05-07 2005-11-24 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
GB0413084D0 (en) * 2004-06-11 2004-07-14 Cipla Ltd Process
US7425648B2 (en) 2005-01-03 2008-09-16 A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. Process for the preparation of nateglinide, preferably in B-form
CN101111266A (zh) * 2005-01-31 2008-01-23 味之素株式会社 含有降血糖药的用于改善或治疗糖耐量异常、临界性糖尿病、胰岛素抵抗性和高胰岛素血症的药物组合物
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US20070060528A1 (en) 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
WO2007056387A2 (en) * 2005-11-07 2007-05-18 Elixir Pharmaceuticals, Inc. Combinations of metformin and meglitinide
US7615649B2 (en) 2006-01-26 2009-11-10 Iowa State University Research Foundation, Inc, Synthesis of polycyclic procyanidins
WO2007113650A2 (en) * 2006-04-05 2007-10-11 Cadila Pharmaceuticals Limited A novel and improved process fro the preparation of nateglinide and its polymorph form-h
CN100383114C (zh) * 2006-07-21 2008-04-23 杭州保灵有限公司 一种那格列奈的制备工艺
WO2009137082A1 (en) * 2008-05-08 2009-11-12 Concert Pharmaceuticals, Inc. 4-isopropylcyclohexylcarbonyl amino acid derivatives
ES2459468T3 (es) 2009-05-15 2014-05-09 Novartis Ag Arilpiridinas como inhibidores de aldosterona sintasa
WO2010136474A2 (en) 2009-05-28 2010-12-02 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
MY156270A (en) 2009-05-28 2016-01-29 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
CN102712589B (zh) 2009-11-17 2015-05-13 诺华股份有限公司 作为醛固酮合酶抑制剂的芳基-吡啶衍生物
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
ES2472446T3 (es) 2009-11-30 2014-07-01 Novartis Ag Derivados de imidazol como inhibidores de aldosterona sintasa
HRP20140114T1 (hr) 2010-02-03 2014-03-14 Takeda Pharmaceutical Company Limited Inhibitori kinaze 1 koji reguliraju signal apoptoze
CA2802455A1 (en) 2010-06-14 2011-12-22 Cipla Limited A process for the preparation of nateglinide
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
WO2012095548A2 (es) 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compuestos para el tratamiento de enfermedades neurodegenerativas
WO2013066277A1 (en) 2011-11-03 2013-05-10 Mahmut Bilgic Synergic compositions
WO2013077819A1 (en) 2011-11-23 2013-05-30 Mahmut Bilgic Pharmaceutical formulations comprising nateglinide
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
HUE038248T2 (hu) 2013-02-14 2018-10-29 Novartis Ag Helyettesített biszfenil-bután-foszfonsav származékok, mint NEP (semleges endopeptidáz) inhibitorok
PE20160991A1 (es) 2013-07-25 2016-10-15 Novartis Ag Bioconjugados de polipeptidos de apelina sintetica
UY35670A (es) 2013-07-25 2015-02-27 Novartis Ag Polipéptidos cíclicos para el tratamiento de insuficiencia cardíaca
SG11201704758XA (en) 2015-01-23 2017-08-30 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
EP3096122B1 (en) 2015-05-20 2017-05-31 CORGHI S.p.A. Balancing machine
CN108602758B (zh) 2016-02-05 2021-01-26 斯福瑞股份公司 制备反式-4-氨基-1-环己烷基羧酸及其衍生物的方法
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT377496B (de) * 1981-06-19 1985-03-25 Voith Gmbh J M Vorrichtung zum anwickeln einer warenbahn auf eine neu eingelegte wickelhuelse in einer doppeltragwalzen-wickelmaschine
DE3382112D1 (de) * 1982-04-30 1991-02-21 Ajinomoto Kk Pharmazeutische zusammensetzung.
JPS58189121A (ja) * 1982-04-30 1983-11-04 Ajinomoto Co Inc インシユリン投与賦活剤

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0395717U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1990-01-23 1991-09-30
WO1998022105A1 (fr) * 1996-11-15 1998-05-28 Ajinomoto Co., Inc. Preparation en comprimes
US6143323A (en) * 1996-11-15 2000-11-07 Ajinomoto Co., Inc. Tablet composition
KR100873585B1 (ko) * 2000-03-17 2008-12-11 아지노모토 가부시키가이샤 당뇨병성 합병증용 약제
WO2001068136A1 (fr) * 2000-03-17 2001-09-20 Ajinomoto Co., Inc. Medicaments permettant de traiter les complications du diabete et des neuropathies et utilisation de ces medicaments
US7659428B2 (en) 2000-10-18 2010-02-09 Ajinomoto Co., Inc. Methods for producing acylphenylalanine
WO2002034713A1 (fr) * 2000-10-24 2002-05-02 Ajinomoto Co.,Inc. Procede de production de cristaux de nateglinide a forme b
US7544834B2 (en) 2000-10-24 2009-06-09 Ajinomoto Co., Inc. Methods for producing nateglinide B-type crystals
JP2005519949A (ja) * 2002-03-11 2005-07-07 ノバルティス アクチエンゲゼルシャフト ナテグリニドの塩
JP2005522503A (ja) * 2002-04-15 2005-07-28 ノバルティス アクチエンゲゼルシャフト Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形
JP2007526890A (ja) * 2003-07-10 2007-09-20 リヒター ゲデオン ベジェセティ ジャール アール．テー． キラル純ｎ−（トランス−４−イソプロピル−シクロヘキシルカルボニル）−ｄ−フェニルアラニン及びそれらの結晶構造変性体の生成方法
JP2007505059A (ja) * 2003-09-11 2007-03-08 ゾルファイ フルーオル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｎ−アシル化合物の製造
WO2007119580A1 (ja) * 2006-03-31 2007-10-25 Ajinomoto Co., Inc. カルボン酸クロリド化合物の製造方法
JP5152699B2 (ja) * 2006-03-31 2013-02-27 味の素株式会社 カルボン酸クロリド化合物の製造方法
KR101399916B1 (ko) * 2006-03-31 2014-05-28 아지노모토 가부시키가이샤 카복실산 클로라이드 화합물의 제조방법
WO2017090656A1 (ja) * 2015-11-27 2017-06-01 住友化学株式会社 トランス－シクロヘキサンカルボン酸の製造方法

Also Published As

Publication number Publication date
JPH0415221B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-03-17
EP0196222B1 (en) 1992-01-29
DE10199054I2 (de) 2006-04-27
EP0196222A3 (en) 1988-02-24
USRE34878E (en) 1995-03-14
DE10199054I1 (de) 2002-01-10
US4816484A (en) 1989-03-28
EP0196222A2 (en) 1986-10-01
DE3683662D1 (de) 1992-03-12

Similar Documents

Publication Publication Date Title
JPS6354321A (ja) 血糖降下剤
JPS62161728A (ja) 抗菌剤
JP2004359676A (ja) 置換チアゾリジンジオン誘導体
US4234584A (en) Substituted phenylpiperazine derivatives
JPS5849366A (ja) ３，４−ジヒドロカルボスチリル誘導体
US3755413A (en) 1-cyanophenoxy-2-hydroxy-3-(cycloalkyl-amino)-propanes
JPS6038357A (ja) チオエーテル、その製造法及びこの化合物を含有しアレルギー性疾患を撲滅する薬剤
JPH0667919B2 (ja) 新規なインデノチアゾ−ル誘導体及びその製造法
EP0111226A1 (en) Carboximide derivatives, process for their production and medicines containing same
FR2460294A1 (fr) Nouveaux oxime-ethers, leur procede de preparation et compositions pharmaceutiques les contenant
EP0143016B1 (fr) Dérivés de 4-(3-alkynyloxy-2-hydroxy-propyl)-piperazin-1-yl-N-phényl acétamide, leur préparation et leur application en thérapeutique
IE43797B1 (en) Esters of indole-derived amino alcohols
US3914219A (en) 3-Alkyl-4-sulfamoyl-aniline compounds
US4018818A (en) Hydroxyl-substituted 2-chloro-α-(tert-butylaminomethyl)-benzylalcohols
US3813398A (en) Benzenesulfonyl-semicarbazides and process for their manufacture
US4143143A (en) Substituted imidazo[5,1-a]isoquinolines
US4117131A (en) Method of inhibiting gastric acid secretions with 2-(4-pyrimidinyl)thioacetamides
US3917833A (en) Amino-substituted benzocycloheptenones for inducing sleep
JPS6130588A (ja) ベンゾ〔ｃ〕〔１，８〕ナフチリジン、その製造方法及びその使用、並びにこれらの化合物を含有する調製剤
KR850000210B1 (ko) 옥사졸린의 제조방법
US4980352A (en) Gem-dimethyl substituted bicyclic compounds useful as eukalemic diuretics
US3903165A (en) Ethynylaryl amines and processes for their preparation
JPH02292213A (ja) 制癌剤
US3948899A (en) α-Cyanobenzylpiperazines and a process for producing the same
US3939269A (en) Benzenesulfon YL-semicarbazides for lowering blood sugar levels

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120317

Year of fee payment: 20